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Background: All lentiviruses except equine infectious anemia virus (EIVA) antagonize antiviral family APOBEC3 (A3)
proteins of the host through viral Vif proteins. The mechanism by which Vif of human, simian or feline
immunodeficiency viruses (HIV/SIV/FIV) suppresses the corresponding host A3s has been studied extensively.
Results: Here, we determined that bovine immunodeficiency virus (BIV) and maedi-visna virus (MVV) Vif proteins
utilize the Cullin (Cul)-ElonginB (EloB)-ElonginC (EloC) complex (BIV Vif recruits Cul2, while MVV Vif recruits Cul5)
to degrade Bos taurus (bt)A3Z2-Z3 and Ovis aries (oa)A3Z2-Z3, respectively, via a proteasome-dependent but a
CBF-β-independent pathway. Mutation of the BC box in BIV and MVV Vif, C-terminal hydrophilic replacement of
btEloC and oaEloC and dominant-negative mutants of btCul2 and oaCul5 could disrupt the activity of BIV and
MVV Vif, respectively. While the membrane-permeable zinc chelator TPEN could block BIV Vif-mediated degradation of
btA3Z2-Z3, it had minimal effects on oaA3Z2-Z3 degradation induced by MVV Vif, indicating that Zn is important for
the activity of BIV Vif but not MVV Vif. Furthermore, we identified a previously unreported zinc binding loop
[C-x1-C-x1-H-x19-C] in the BIV Vif upstream BC box which is critical for its degradation activity.
Conclusions: A novel zinc binding loop was identified in the BIV Vif protein that is important for the E3
ubiquination activity, suggesting that the degradation of btA3Z2-Z3 by BIV and that of oaA3Z2-Z3 by MVV
Vif may need host factors other than CBF-β.
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Lentiviruses, a subfamily of retroviruses, cause slow infec-
tions in humans and animals. Human immunodeficiency
virus type 1 (HIV-1), simian immunodeficiency virus
(SIV), caprine arthritis-encephalitis virus (CAEV), fe-
line immunodeficiency virus (FIV), bovine immunodefi-
ciency virus (BIV), maedi-visna virus (MVV) and equine
infectious anemia virus (EIAV) are lentiviruses that infect
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unless otherwise stated.respectively. Except for EIAV, all lentiviruses require the
accessory protein viral infectivity factor (Vif) to establish
persistent infection and pathogenesis in vivo [1]. The Vif
protein counteracts the antiviral activities of the apolipo-
protein B mRNA-editing enzyme, catalytic polypeptide-
like 3 (APOBEC3 or A3) proteins of the host [2]. These
A3 proteins possess broad antiviral activities for many vi-
ruses as natural host restriction factors [3-7]. Among the
A3 proteins, A3G is the most intensively studied. In the
late stage of viral infection, A3G proteins are packaged
into virions and induce dC to dU mutations in newly syn-
thesized minus-strand viral DNA. These mutations cause
abnormal expression of viral proteins, resulting in disrup-
tions of the viral life cycle [8-10]. The HIV-1 accessoryLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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replication in non-permissive cell lines [11]. HIV-1 Vif
antagonizes the antiviral activity of the cellular protein
A3G by recruiting the transcription cofactor CBF-β and
ElonginB (EloB)-ElonginC (EloC) to the Cullin5 (Cul5)-
Rbx complex to degrade A3G [3,12-18]. The functional
domains that Vif uses to form the E3 ligase complex
have been reported. The main sites involved in the
interaction with A3G and CBF-β are in the N-terminal
region of Vif [19-23]. The H-x5-C-x17– 18-C-x3 –5-H
motif (i.e., HCCH zinc finger) and the PPLPx4L motif
(also known as the Cul5 box) in the C-terminal region
of HIV-1 Vif mediate selective binding to Cul5 [24-26].
Meanwhile, another C-terminal SLQ(Y/F) LA motif (BC
box) downstream of the HCCH domain binds with EloC
to assemble the E3 ligase complex [12,27,28]. Mechanisms
of the degradation of APOBEC3 proteins induced by SIV
Vif and FIV Vif also have been well studied. SIVmac239
Vif recruits the transcription cofactor CBF-β and EloB-EloC
to the Cul5-Rbx complex, forming the CBF-β-Cul5-EloB-
EloC E3 ubiquitin ligase to degrade the cellular antiviral pro-
tein A3G [29,30]. FIV Vif interacts with feline Cul5, EloB
and EloC to form an E3 complex to induce degradation of
fA3s [31].
BIV affects the immune system like many other lenti-
viruses [32,33], and its name was based on similarities
to HIV-1 in genetic, structural, antigenic and biological
factors. BIV infects cattle and causes significant but
non-persistent infiltrating lymphocytes and follicular
hyperplasia in the hemolymph nodes [34]. MVV is also
a lentivirus which causes slowly progressive menin-
goencephalomyelitis and pneumonia in sheep [35]. The
Vif proteins of BIV and MVV are both indispensable for
viral infectivity [36]. The artiodactyl A3 proteins have been
reported to have an active N-terminal DNA cytosine de-
aminase domain, which displays a dinucleotide deamin-
ation preference [37]. According to the nonprimate A3
nomenclature, there are four Bos taurus A3 (btA3) pro-
teins: btA3Z1, btA3Z2, btA3Z3, btA3Z2-Z3 and four Ovis
aries A3 (oaA3) proteins: oaA3Z1, oaA3Z2, oaA3Z3 and
oaA3Z2-Z3. Among the A3 proteins, A3Z2-Z3 is the only
double domain protein that displays fully intact levels of
lentivirus restriction and is neutralized by Vif from several
different species [38]. BIV and MVV Vif are known to de-
grade the host A3 proteins to antagonize their antiviral ac-
tivity. However, whether the mechanism by which Vif of
BIV and MVV neutralize the btA3s and oaA3s, respect-
ively, is similar to that of HIV-1 Vif against human A3G
remains an open question.
In our study, we chose btA3Z2-Z3 and oaA3Z2-Z3 as
the target proteins to investigate the mechanism of their
degradation by BIV Vif and MVV Vif proteins, respect-
ively. Interactions of BIV and MVV Vif with Cul, EloB,
EloC and/or CBF-β as part of an E3 ubiquitin ligasecomplex in the corresponding host cells also were examined.
BIV Vif was shown to specifically interact with btCul2 (and
MVV Vif with oaCul5). The function of BIV Vif and its
interaction with Cul2 were explored further by mutations of
the C-x1-C-x1-H-x19-C (CCHC) motif which may be a novel
zinc finger (18, 46). Homology modeling results showed that
this CCHC motif is likely a zinc binding loop. Together, re-
sults of this study indicate that BIV and MVV Vifs bind with
SOCS proteins in a novel manner to form Elo-Cul-SOCS
box (ECS) complexes, which may facilitate future studies of
virus-host interactions.
Results
BIV and MVV Vifs degrade btA3Z2-Z3 and oaA3Z2-Z3,
respectively, via a proteasomal pathway and affect the
synthesis rate rather than the stability of these A3 proteins
Human A3G is known to be degraded by HIV-1 Vif in a
proteasome-dependent manner. Studies in recent years have
shown that BIV and MVV Vifs can degrade btA3Z2-Z3
and oaA3Z2-Z3, respectively, which allows for effective
infection by the corresponding virus (BIV or MVV).
However, the molecular mechanism by which BIV Vif
degrades btA3Z2-Z3 or MVV Vif degrades oaA3Z2-Z3
is still unclear. To determine whether the degradation
of btA3Z2-Z3 by BIV Vif is proteasome-dependent,
293 T cells were co-transfected with HA-tagged btA3Z2-Z3
and cmyc-tagged BIV Vif or VR1012 and treated with the
proteasome inhibitor MG132 [39] or DMSO as a negative
control. The results showed that btA3Z2-Z3 could be de-
graded by BIV Vif (Figure 1A, lane 2). However, MG132
blocked the degradation of btA3Z2-Z3 and stabilized the
BIV Vif protein (Figure 1A, lane 4), implying that the deg-
radation of btA3Z2-Z3 protein depends on proteasome
activity similar to HIV-1 Vif. When 293 T cells were co-
transfected with HA-tagged oaA3Z2-Z3 and cmyc-tagged
MVV Vif or VR1012 and treated with the proteasome
inhibitor MG132 or DMSO as a negative control, the ex-
perimental results were nearly the same as those above
(Figure 1B). These findings imply that BIV Vif degrades
btA3Z2-Z3 and MVV Vif degrades oaA3Z2-Z3 via a pro-
teasomal pathway, and inhibiting this process would in-
crease the expression of these APOBEC3 proteins to
varying degrees.
To assess the steady-state level of cell-associated A3Z2-
Z3 in the absence or presence of Vif, the cycloheximide
(CHX, protein synthesis inhibitor) stability assay was per-
formed (Figure 1C, D). Two sets of experiments were car-
ried out. 293 T cells were co-transfected with HA-tagged
btA3Z2-Z3 (30 ng) or HA-tagged oaA3Z2-Z3 (15 ng) and
cmyc-tagged BIV Vif, cmyc-tagged MVV Vif (200 ng) or
VR1012. After 18 h of transfection, transfected cells in the
first set were treated with CHX, while those in the second
set were treated with DMSO as a control. We then checked
the expression level of A3Z2-Z3 in the absence or presence
Figure 1 BIV/MVV Vif affect the synthesis rate of btA3Z2-Z3/oaA3Z2-Z3, respectively, via a proteasomal pathway. (A, B) 293 T cells
(0.5 × 106) were transfected with HA-tagged btA3Z2-Z3 (30 ng) or oaA3Z2-Z3 (15 ng) and cmyc-tagged BIV Vif (200 ng) or MVV Vif (200 ng) or
VR1012. After 36 h of transfection, the cells were treated with the proteasome inhibitor MG132 (10 μM) (lanes 3, 4) or control DMSO (lanes 1, 2).
At 48 h after transfection, the cells were harvested for Western blotting using anti-HA, anti-cmyc and anti-tubulin antibodies. Percentages of
degradation with DMSO or MG132 treatment were calculated. (C, D) 293 T cells (0.5 × 106) were transfected with HA-tagged btA3Z2-Z3 (30 ng) or
oaA3Z2-Z3 (15 ng) and cmyc-tagged BIV Vif (200 ng) or MVV Vif (200 ng) or VR1012. After 18 h of transfection, the cells were treated with the protein
synthesis inhibitor CHX (100 μg/ml) or DMSO as control and then harvested at the indicated time points for Western blot analysis using anti-HA and
anti-cmyc antibodies. Percentages of A3 in the presence of Vif relative to that in the absence of Vif with DMSO or MG132 treatment were calculated.
All degradation experiments were repeated five times. The mean value ± SEM of the remaining btA3Z2-Z3 precentage after degradation is 18.5 ± 5.2%
(P < 0.01); The mean value and SEM of the remaining oaA3Z2-Z3 precentage after degradation is 27.8% ± 6.4% (P < 0.01).
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24 h after CHX or DMSO treatment. With the addition of
CHX, the synthesis of Vif and A3Z2-Z3 was inhibited, and
most of the pre-existing A3Z2-Z3 was degraded by Vif,
Meanwhile, Vif was partially degraded by the EloB-EloC-Cul
E3 ligase. In the DMSO-treated set of cells in which protein
synthesis was not inhibited, quantities of A3Z2-Z3 and Vif
increased over time (compare A3Z2-Z3 levels at 0 h, 6 h,
12 h and 24 h in the presence of Vif in Figure 1C, D).
Under this condition, A3Z2-Z3 was still remarkably de-
graded by Vif (compare A3Z2-Z3 levels in the absenceand presence of Vif in Figure 1C, D). These results re-
vealed that BIV and MVV Vifs could efficiently degrade
btA3Z2-Z3 and oaA3Z2-Z3, respectively.
BIV Vif combines with Cul2, EloB and EloC and MVV Vif
combines with Cul5, EloB and EloC to induce proteasomal
degradation of btA3Z2-Z3 and oaA3Z2-Z3, respectively
HIV-1 Vif interacts with human Cul5, EloB and EloC to
form the E3 complex, which degrades human A3G. A re-
cent study showed that CBF-β is involved in this degrad-
ation process as well [3,12-17]. Therefore, we wondered
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of A3 proteins by BIV and MVV Vif are the same or simi-
lar to those for HIV-1 Vif. Initially, we investigated the en-
dogenous proteins involved in the degradation process by
transfecting HA-tagged BIV Vif or HA-tagged MVV Vif
into MDBK or MDOK cells; however, we did not obtain
clear and convincing results due to the low transfection
efficiency in these cells. Amino acid sequence alignments
showed that the homologies of EloB, EloC, Cul2, Cul5 and
CBF-β between humans, cattle and sheep exceed 98.0%
(Table 1). Therefore, we attempted to study this issue
by transfecting HA-tagged BIV Vif and HA-tagged von
Hippel-Lindau (VHL) tumor suppressor (as a positive
control for binding with Cul2), HA-tagged MVV Vif and
HA-tagged HIV Vif (as a positive control for binding with
Cul5) or negative vector control VR1012 into 293 T cells
to perform a co- immunoprecipitation assay. Cell lysates
were immunoprecipitated with HA beads, followed by
SDS-PAGE and immunoblot analysis using anti-HA,
anti-hCul2 anti-hCul5, anti-hEloB, anti-hEloC and anti-
hCBF-β antibodies. The experimental results showed that
the BIV Vif protein was capable of binding to endogenous
Cul2, EloB and EloC proteins, but not with Cul5 or CBF-β
(Figure 2A). Notably, the negative control HA-tagged
VHL did not bind with CBF-β (Figure 2B). Meanwhile, the
MVV Vif protein was capable of binding to endogenous
Cul5, EloB and EloC proteins, but not with Cul2 or CBF-β
(Figure 2C). The co-immunoprecipitation assay showed
that BIV Vif recruited Cul2, EloB and EloC, while MVV
Vif recruited Cul5, EloB and EloC, to form the E3
complex to induce the degradation of btA3Z2-Z3 and
oaA3Z2-Z3, respectively. Of the various Vif proteins,
BIV Vif appears to be unique by recruiting Cul2, and
CBF-β was not found to be involved in the degradation
of A3Z2-Z3 mediated by either BIV Vif or MVV Vif.
BIV Vif interacts with btCul2 and btEloC directly but not
with btCBF-β, and MVV Vif interacts with oaCul5 and
oaEloC directly but not with oaCBF-β
In order to further confirm the cellular proteins involved
in BIV Vif-mediated degradation of btA3Z2-Z3, 293 T
cells were transiently co-transfected with cmyc-tagged
BIV Vif and Flag-tagged btCBF-β or HA-tagged btEloC
(or HA-tagged BIV Vif and cmyc-tagged btCul2 or cmyc-
tagged btCul5). Subsequently, co-immunoprecipitationTable 1 Homology rates of EloB, EloC, Cul2, Cul5 and
CBF-β between humans, cattle and sheep
Species Protein (% identity of amino acids)
EloB EloC Cul2 Cul5 CBFβ
Homo sapiens/Bos taurus 98.3 100.0 99.7 100.0 100.0
Homo sapiens/Ovis aries 98.3 100.0 98.5 100.0 100.0
Bos taurus/Ovis aries 100.0 100.0 98.3 100.0 100.0experiments were performed to explore the interaction
between BIV Vif and btCBF-β, btEloC, btCul2 and btCul5.
After 48 h of transfection, cells were immunoprecipitated
with HA beads or with an anti-cmyc antibody followed by
SDS-PAGE and immunoblot analysis using an anti-HA
antibody and an anti-cmyc antibody. The results revealed
that BIV Vif could directly interact with btCul2, but not
with btCul5 or btCBF-β (Figure 3A, D, G). BIV Vif could
also bind with btEloC (data not shown). Of note, the
btCBF-β-independent function of BIV Vif has been re-
ported previously [14]. The same experiments were carried
out as mentioned above for MVV Vif. The results revealed
that MVV Vif could directly interact with oaCul5 and oaE-
loC, but not with oaCul2 or oaCBF-β (Figure 3B, E, H).
MVV Vif could also interact with oaEloC (data not shown).
293 T cells were transiently co-transfected with cmyc-
tagged HIV Vif and Flag-tagged hCBF-β (or HA-tagged
HIV Vif and cmyc- tagged hCul5), HA-flagged hVHL and
cmyc-tagged hCul2 as positive controls (Figure 3C, F, I).
Mutation of BC box in BIV and MVV Vif or C-terminal
hydrophilic residue replacement in btEloC and oaEloC can
disrupt the activity of these Vif proteins against btA3Z2-Z3
and oaA3Z2-Z3, respectively
Lentiviral Vif proteins represent substrate receptor pro-
teins that contain relatively conserved BC-box motifs.
The known BC-box motif of HIV-1, SIVmac239, BIV and
MVV Vifs is SLQ, and that of FIV Vif is TLQ [27,40]. In
this study, we replaced the SLQ sequence of BIV Vif and
MVV Vif with AAA in order to explore whether the BC
box is critical for the degradation of btA3Z2-Z3 and
oaA3Z2-Z3 induced by BIV Vif and MVV Vif, respect-
ively. To investigate role of the SLQ motif in BIV Vif,
293 T cells were transfected with HA-tagged btA3Z2-Z3
and cmyc-tagged BIV Vif or cmyc-tagged BIV Vif SLQ-
AAA. Likewise, the function of the SLQ motif in MMV
Vif was examined by transfecting 293 T cells with HA-
tagged oaA3Z2-Z3 and cmyc-tagged MVV Vif or cmyc-
tagged MVV Vif SLQ-AAA. At 48 h after transfection,
the cells were harvested for Western blotting using
anti-HA, anti-cmyc and anti-tubulin antibodies. The
results revealed that BIV Vif and MVV Vif SLQ-AAA
respectively lost the ability to degrade btA3Z2-Z3 and
oaA3Z2-Z3 (Figure 4A, lane 3; Figure 4B, lane 3), sug-
gesting that the BC-box motif of each of these two Vif
proteins is critical for the degradation of the correspond-
ing A3Z2-Z3 target. These results are consistent with a
previous report showing that the BIV Vif SLQ-AAA and
MVV Vif SLQ-AAA mutants have altered function and
fail to degrade btA3Z3 and oaA3Z2-Z3 proteins, respect-
ively [40] .
To further confirm the significance of EloC in the E3
ligase, we constructed btEloC and oaEloC mutants by
replacement of critical hydrophobic amino acids A100
Figure 2 BIV Vif recruits Cul2-EloB-EloC and MVV Vif recruits Cul5-EloB-EloC to induce btA3Z2-Z3 and oaA3Z2-Z3 degradation. 293 T
cells (5 × 106) were transfected with 10 μg HA-tagged BIV Vif or 10 μg VHL and 10 μg VR1012 as a positive and a negative control, respectively
(A, B); or with 10 μg HA-tagged MVV Vif or 10 μg HIV Vif and 10 μg VR1012 as a positive and a negative control, respectively (C, D). After 48 h
of transfection, cell lysates were immunoprecipitated with HA beads, followed by SDS-PAGE and immunoblot analysis using anti-HA, anti-hCul2,
anti-hCul5, anti-hEloB, anti-hEloC and anti-hCBF-β antibodies. All immunoprecipitation experiments were repeated three times.
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transfected with HA-tagged btA3Z2-Z3 and cmyc-tagged
BIV Vif or VR1012 with HA-tagged btEloCΔ2 or HA-
tagged btEloC as a control. In a parallel experiment, 293 T
cells were transfected with HA-tagged oaA3Z2-Z3 and
cmyc-tagged MVV Vif or VR1012 with HA-tagged oaE-
loCΔ2 or HA-tagged oaEloC as a control. At 48 h after
transfection, the cells were harvested for Western blotting
using anti-HA, anti-cmyc and anti-tubulin antibodies.
Addition of EloCΔ2 rescued the levels of both btA3Z2-Z3
and oaA3Z2-Z3 (Figure 4C, lane 4; Figure 4D, lane 4).
These results indicated that EloC takes part in the degrad-
ation of btA3Z2-Z3 by BIV Vif and of oaA3Z2-Z3 by
MVV Vif.
Dominant-negative btCul2 and oaCul5 mutants can inhibit
the activity of BIV Vif against btA3Z2-Z3 and MVV Vif
against oaA3Z2-Z3,respectively, and Zn is important for BIV
Vif activity
All Cullin family members are known to be modulated
by the ubiquitin-like small molecule Nedd8, which is
critical for E3 ubiquitin ligase activity [42]. To further
confirm the participation of btCul2 and oaCul5 in the
degradation of btA3Z2-Z3 and oaA3Z2-Z3, we constructed
dominant-negative btCul2 and oaCul5 mutants and deter-
mined their effect on the degradation of btA3Z2-Z3 and
oaA3Z2-Z3 induced by BIV and MVV Vif, respectively.
293 T cells were transfected with HA-tagged btA3Z2-Z3
and cmyc-tagged BIV Vif or VR1012, with cmyc-tagged
btCul2ΔNedd8 or with a control vector expressing cmyc-
tagged hCul1K720R, which is a dominant-negative hCul1
mutant [43]. In parallel, another set of 293 T cells was
transfected with HA-tagged oaA3Z2-Z3 and cmyc-tagged
MVV Vif or VR1012, with cmyc-tagged oaCul5ΔNedd8 orwith the cmyc-tagged hCul1K720R control vector. As
a positive control for the downregulation of hA3G by
hCul5ΔNedd8, 293 T cells were transfected with HA-
tagged hA3G and cmyc-tagged HIV Vif or VR1012,
with cmyc-tagged hCul5ΔNedd8 or the cmyc-tagged
hCul1K720R control vector. At 48 h after transfection,
the cells were harvested for Western blotting using anti-
HA, anti-cmyc and anti-tubulin antibodies. As expected,
the expression of btCul2ΔNedd8 and oaCul5ΔNedd8 could
up-regulate the amount of btA3Z2-Z3 and oaA3Z2-Z3, re-
spectively (Figure 5A, lane 4; Figure 5B, lane 4). The results
indicated that btCul2 and oaCul5 are recruited to the
Cul-E3 complex.
Cellular proteins assemble with Cul-EloB-EloC E3 com-
plexes through a BC box and a downstream Cul box [44].
Some cellular proteins such as the tumor suppressor VHL
use a Cul2 box to bind with Cul2, while others such as
SOCS3 use a Cul5 box to bind with Cul5 [44,45]. Primate
lentiviral (HIV-1/SIV) Vif proteins use a zinc-binding
HCCH motif to interact with Cul5 [25]. FIV Vif has nei-
ther a Cul5 box nor an HCCH motif, but it still interacts
with Cul5 in a novel fashion [31]. Since BIV and MVV Vif
have no apparent Cul2 or Cul5 box or an HCCH motif,
we wondered whether Zn is significant for its interaction
with btCul2 and oaCul5. In order to explore this issue, we
used the membrane-permeable zinc chelator TPEN [46]
to determine its effects on the BIV and MVV Vif-mediated
degradation of btA3Z2-Z3 and oaA3Z2-Z3, respectively.
293 T cells were transfected with HA-tagged btA3Z2-Z3
and cmyc-tagged BIV Vif or VR1012. A parallel set of
293 T cells was transfected with HA-tagged oaA3Z2-Z3
and cmyc-tagged MVV Vif or VR1012. After 36 h of
transfection, the cells were treated with TPEN at 3.5 μM
(Figure 5D, lanes 3, 4; Figure 5E, lanes 3, 4) or DMSO
Figure 3 BIV Vif interacts with btCul2 and MVV Vif with oaCul5, while CBF-β are not involved. (A–C) 293 T cells (5 × 106) were co-transfected
with 5 μg cmyc-tagged BIV Vif (MVV Vif or HIV Vif) and 5 μg VR1012, 5 μg Flag-tagged btCBF-β (oaCBF-β or hCBF-β) and 5 μg VR1012, 5 μg cmyc-tagged
BIV Vif (MVV Vif or HIV Vif) and 5 μg Flag-tagged btCBF-β (oaCBF-β or hCBF-β). At 48 h after transfection, cell lysates were co-immunoprecipitated with an
anti-cmyc antibody, followed by SDS-PAGE and immunoblot analysis using anti-cmyc and anti-Flag antibodies. (D-F) 293 T cells (5 × 106) were co-transfected
with 6 μg HA-tagged BIV Vif (MVV Vif, or pVHL) and 10 μg VR1012, 10 μg cmyc-tagged btCul2 (oaCul2 or hCul2) and 6 μg VR1012, 6 μg HA-tagged BIV Vif
(MVV Vif or pVHL) and 10 μg cmyc-tagged btCul2 (oaCul2 or hCul2). Cells were co-immunoprecipitated with HA beads followed by SDS-PAGE
and immunoblot analysis using anti-HA and anti-cmyc antibodies. (G-I) 293 T cells (5 × 106) were co-transfected with 4 μg HA-tagged BIV Vif
(MVV Vif or HIV Vif) and 8 μg VR1012, 8 μg cmyc-tagged btCul5 (oaCul5 or hCul5) and 4 μg VR1012, 4 μg HA-tagged BIV Vif (MVV Vif or HIV Vif)
and 8 μg cmyc-tagged btCul5 (oaCul5 or hCul5). Cells were co-immunoprecipitated with HA beads followed by SDS-PAGE and immunoblot analysis
using an anti-HA and anti-cmyc antibodies. All co-immunoprecipitation experiments were repeated three times.
Zhang et al. Retrovirology 2014, 11:77 Page 6 of 14
http://www.retrovirology.com/content/11/1/77(Figure 5D, lanes 1, 2; Figure 5E, lanes 1, 2). At 48 h after
transfection, the cells were harvested for Western blotting
using anti-HA, anti-cmyc and anti-tubulin antibodies. The
results showed that the addition of TPEN blocked the deg-
radation of btA3Z2-Z3 induced by BIV Vif (Figure 5D,
lane 4), but it had a minimal effect on the degradation of
oaA3Z2-Z3 induced by MVV Vif (Figure 5E, lane 4).
These findings indicated that Zn is important for the activ-
ity of BIV Vif, but it is not required for the activity of MVV
Vif. We propose that a zinc finger domain is involved in
the BIV Vif-mediated degradation of btA3Z2-Z3, while
MVV Vif may have a yet undefined mechanism for inter-
acting with oaCul5, which is similar to FIV Vif.
CCHC motif is crucial for activity of BIV Vif and its
interaction with Cul2
In order to further explore the mechanism of the inter-
action between BIV Vif and btCul2, we conducted an in-depth analysis of the BIV Vif sequence. A putative zinc
binding motif H-x8-C-x1-C-x1-H-x19-C-x14-H was found
upstream of the BC box. To explore whether this puta-
tive motif is a functional domain for the activity of BIV
Vif, we constructed a series of BIV Vif single mutants in
which histidines and cysteines (H102, C111, C113, H115,
C134, and H149) were replaced individually with leucine
or serine and a BIV Vif double mutant containing two
amino acids (C111 and C113) replaced with serine. 293 T
cells were co-transfected with HA-tagged btA3Z2-Z3
and cmyc-tagged BIV Vif, cmyc-tagged BIV Vif H102L,
cmyc-tagged BIV Vif C111S, cmyc-tagged BIV Vif C113S,
cmyc-tagged BIV Vif H115L, cmyc-tagged BIV Vif C134S,
cmyc-tagged BIV Vif H149L or cmyc-tagged BIV Vif
C111S/C113S. At 48 h after transfection, the cells were
harvested for Western blotting using anti-HA, anti-cmyc
and anti-tubulin antibodies. The results revealed that BIV
Vif C111S, BIV Vif C113S, BIV Vif H115L and BIV Vif
Figure 4 Mutants of BIV/MVV Vif BC box and btEloC/oaEloC can disrupt the activity of BIV/MVV Vif. 293 T cells (0.5 × 106) were co-transfected
with (A) 30 ng HA-tagged btA3Z2-Z3 and 200 ng cmyc-tagged BIV Vif or BIV Vif SLQ-AAA, (B) 15 ng of HA-tagged oaA3Z2-Z3 and
200 ng cmyc-tagged MVV Vif or MVV Vif SLQ-AAA, (C) 30 ng HA-tagged btA3Z2-Z3 and 200 ng cmyc-tagged BIV Vif or VR1012,
adjusted to 500 ng with 300 ng btEloC-HA, btEloCΔ2-HA or VR1012, (D) 15 ng HA-tagged oaA3Z2-Z3 and 200 ng cmyc-tagged MVV
Vif or VR1012, adjusted to 500 ng with 300 ng of HA-tagged oaEloC, HA-tagged oaEloCΔ2 or VR1012. At 48 h after transfection, the cells
were harvested for Western blotting using anti-HA, anti-cmyc and anti-tubulin antibodies. All degradation experiments were repeated five times.
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Z3 (Figure 6B, lanes 4, 5, 6, 7, 9), implying that the C-x1-
C-x1-H-x19-C motif is critical for the degradation activity
of BIV Vif. The BIV Vif CCHC mutant also lost the
ability to suppress the antiviral activity of btA3Z2-Z3
(Figure 6C, D), supporting the hypothesis that the CCHC
motif of BIV Vif is critical for its activity against btA3Z2-
Z3. To further confirm whether the CCHC motif is a crit-
ical domain for interacting with Cul2, 293 T cells were
transiently transfected with cmyc-tagged btCul2 and
VR-BIV Vif C111S/C113S-HA. BIV Vif was used as a
positive control. Subsequently, co-immunoprecipitation
experiments were performed to explore the interaction
between btCul2 and BIV Vif or BIV Vif C111S/ C113S.
After 48 h of transfection, cells were immunoprecipitated
with HA beads or with an anti-cmyc antibody, followed by
SDS-PAGE and immunoblot analysis using an anti-HA
antibody and an anti-cmyc antibody. The results revealed
that double mutations in the CCHC motif of BIV Vif
could completely block the interaction between BIV Vif
and btCul2 (Figure 6E). However, this CCHC motif is dif-
ferent from all previously reported zinc finger structures(46), including the HCCH zinc finger in primate lentiviral
Vifs. To further explore whether it is a zinc finger, we built
a homology model for this potential zinc binding domain
of BIV Vif (Figure 6F, G). The model implies this motif
should be able to form a proper zinc coordination site. Al-
though this motif is unlike all previously reported zinc fin-
gers, the sequence and potential zinc coordinated motif of
this domain are similar to those of “zinc binding loops”, as
described previously [47].
Discussion
Mechanisms of BIV Vif- and MVV Vif-induced degradation
of btA3Z2-Z3 and oaA3Z2-Z3 differ by the respective
utilization of Cul2 and Cul5
Based on numerous investigations, HIV-1 Vif is known
to recruit the transcription cofactor CBF-β and EloB-EloC
to the Cul5-Rbx complex, thereby forming the E3 ubiqui-
tin ligase and inducing the degradation of human antiviral
proteins [12-17,28,48]. Other studies have explored further
the degradation mechanisms of SIV Vif against RhA3G
and FIV Vif against feline A3s [29-31]. In the current
study, we investigated the effects of BIV and MVV Vifs on
Figure 5 Dominant-negative btCul2 and oaCul5 mutants block the degradation, while TPEN can inhibit btA3Z2-Z3 degradation.
293 T cells (0.5 × 106) were co-transfected with (A) 30 ng of HA-tagged btA3Z2-Z3 and 200 ng cmyc-tagged BIV Vif or VR1012, adjusted to 500 ng with
300 ng cmyc-tagged btCul2ΔNedd8, a control vector cmyc-tagged hCul1K720R or VR1012, (B) 15 ng HA-tagged oaA3Z2-Z3 and 200 ng cmyc-tagged
MVV Vif or VR1012, adjusted to 500 ng with 300 ng cmyc-tagged oaCul5ΔNedd8, a control vector cmyc-tagged hCul1K720R or VR1012,
(C) 50 ng HA-tagged hA3G and 600 ng cmyc-tagged HIV Vif or VR1012, adjusted to 900 ng with 300 ng cmyc-tagged btCul5ΔNedd8, a
control vector cmyc-tagged hCul1K720R or VR1012. At 48 h after transfection, the cells were harvested for Western blotting using anti-HA,
anti-cmyc and anti-tubulin antibodies. The percentages of btA3Z2-Z3, oaA3Z2-Z3 or hA3G in the presence of btCul2ΔNedd8, oaCul5Δ-
Nedd8 or hCul5ΔNedd8 relative to that in the absence of BIV/MVV/HIV Vif (set to 100%) were calculated. 293 T cells (0.5 × 106) were co-
transfected with (D) 30 ng HA-tagged btA3Z2-Z3 and 200 ng cmyc-tagged BIV Vif or VR1012, (E) 15 ng HA-tagged oaA3Z2-Z3 and 200 ng
cmyc-tagged MVV Vif or VR1012. After 36 h of transfection, the cells were treated with TPEN at 3.5 μM or DMSO as a control. At 48 h after
transfection, the cells were harvested for Western blotting using anti-HA, anti-cmyc and anti-tubulin antibodies. Percentages of degradation
with DMSO or TPEN treatment were calculated.
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First, we found that the proteasome inhibitor MG132 [39]
could block the degradation effect of BIV Vif on btA3Z2-
Z3 and that of MVV Vif on oaA3Z2-Z3, suggesting that
they are proteasome-dependent processes. In addition,
BIV and MVV Vifs were found to affect the synthesis rate
rather than the stability of btA3Z2-Z3 and oaA3Z2-Z3,
respectively. The endogenous immunoprecipitation ex-
periments showed that btEloB, btEloC and btCul2 are
involved in the degradation of btA3Z2-Z3 by BIV Vif.
Correspondingly, oaEloB, oaEloC and oaCul5 are involved
in the degradation of oaA3Z2-Z3 by MVV Vif. Meanwhile,
the host CBF-β proteins do not play a role in this functionof either BIV or MVV Vif. Co-immunoprecipitation assays
further verified the direct interaction of BIV Vif with
btEloC and btCul2, but not with btCBF-β or btCul5. MVV
Vif also was confirmed to directly interact with oaEloC
and oaCul5, but not with oaCBF-β or oaCul2. Similarly,
we found no interaction between FIV Vif and feline
CBF-β (data not shown). CBF-β is reported to regulate
Vif-Cul5 ligase by promoting the folding of primate
lentiviral Vifs (HIV-1 and SIV) [14,29,48,49]. The fact
that other mammalian Vifs do not require the participa-
tion of CBF-β for their function implies that BIV/MVV/
FIV Vif may utilize a different mechanism for recruiting
the Cul-E3 ligase or factors other than CBF-β which have
Figure 6 (See legend on next page.)
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Figure 6 The C-x1-C-x1-H-x19-C motif is crucial and predicted to be a zinc binding loop. (A) Alignment of partial BIV Vif sequences with
primate lentiviral Vifs by BioEdit. (B) 293 T cells (0.5 × 106) were co-transfected with 30 ng HA-tagged btA3Z2-Z3 and 200 ng cmyc-tagged BIV Vif
or BIV Vif mutants H102L, C111S, C113S, H115L, C134S, H149L or C111S/C113S. At 48 h after transfection, the cells were harvested for Western blotting
using anti-HA, anti-cmyc and anti-tubulin antibodies. (C and D) 293 T cells (1 × 106) were co-transfected with 1 μg pNL4-3ΔVif plus 15 ng VR1012, or
HA-tagged btA3Z2-Z3 and 100 ng cmyc-tagged BIV Vif, BIV Vif C111S/C113S or VR1012. The virus infectivity was assayed by the MAGI assay.
Virus infectivity was set to 100% in the absence of btA3Z2-Z3. (D) Western blot was performed on the cell lysates from (C) to show the producer cell levels
of btA3Z2-Z3 protein (anti-HA), BIV Vif/BIV Vif C111S/C113 (anti-cmyc) and tubulin. (E) 293 T cells (5 × 106) were co-transfected with 10 μg cmyc-tagged
btCul2 and 6 μg HA-tagged BIV Vif or 6 μg BIV Vif C111S/C113S. At 48 h after transfection, cells were immunoprecipitated with HA beads, followed by
SDS-PAGE and immunoblot analysis using an anti-HA antibody and an anti-cmyc antibody. (F and G) Panels A and B are views of the alpha
carbon ribbon and differ from each other by 90 degrees. Residues which likely participate in the coordination of zinc ions are shown and
labeled. All infection experiments were repeated three times.
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BIV Vif and that of oaA3Z2-Z3 by MVV Vif.
We constructed an EloC mutant in which the key hydro-
phobic amino acids (A100 and L103) were substituted
with hydrophilic serine, which disrupted the interaction
between the EloC and the BC box of the cellular pro-
teins [41]. These mutations disrupted the degradation
of btA3Z2-Z3 induced by BIV Vif and that of oaA3Z2-Z3
induced by MVV Vif, implicating the involvement of EloC
in the process. Although the sequence homology of lenti-
viral Vifs is poor, they share a highly conserved S/TLQY/
RLA motif, which is a BC box essential for the binding of
EloC [12,27,28]. The SLQ mutations in BIV and MVV Vifs
could block the degradation of btA3Z2-Z3 and oaA3Z2-
Z3, confirming that the BC-box motifs in these Vifs are
essential for the recruitment of the E3 complex. These
two experiments both showed that EloC is a member of
the E3 ligase complex. The participation of btCul2 in
the degradation induced by BIV Vif and that of oaCul5
in the degradation induced by MVV Vif was further
verified by use of dominant-negative btCul2 and oaCul5
mutants. The disruption of BIV Vif-induced degrad-
ation of btA3Z2-Z3 and MVV Vif-induced degradation
of oaA3Z2-Z3 by the corresponding mutants demon-
strated that btCul2 and oaCul5 are required for the BIV
and MVV Vif activity against btA3Z2-Z3 and oaA3Z2-
Z3, respectively.
CCHC motif is crucial for BIV Vif activity and predicted to
be a zinc binding loop
Primate lentiviral Vifs contain a zinc coordination site
H-x5-C-x17– 18-C-x3 –5-H (HCCH) [24-26,48], which de-
termines the selective recruitment of Cul5 by HIV-1 and
SIV Vif. Although FIV Vif does not contain an HCCH
domain, it can still recruit Cul5 [31]. Previous research
has indicated that FIV Vif may utilize a new non-zinc
finger dependent mechanism for interacting with Cul5
[31]. These findings suggest that the Cul2 box and Cul5
box downstream of the BC box or HCCH domain are
not absolutely necessary for the recruitment of Cul2 or
Cul5. In this study, we found a potential zinc finger, the
C-x1-C-x1-H-x19-C motif, which was critical for thedegradation activity of BIV Vif and the interaction with
a Cul protein. This motif is different from all previously
reported zinc finger structures, including the HCCH
zinc finger in primate lentiviral Vifs, but the sequence
and potential zinc coordinated motif of this domain
are almost identical to those of “zinc binding loops”
(45), except the distance between the 3rd (H115) and
4th (C134) residues is much longer in our protein. We
then further analyzed the sequence of this potential
zinc binding domain and found only one hit covering
the full-length sequence of this domain, the crystal
structure of tatD DNase of Escherichia coli, which is
also a metallic ion binding protein [50]. Using this
structure as a template, we built a homology model
for the potential zinc binding domain of BIV Vif. The
model suggests that the entire domain likely forms an
alpha-beta-alpha super secondary structure. The 4th
residue of this potential zinc domain folds back through this
structure and is distally close to the other three residues.
Thus, they should be able to form a proper zinc coordin-
ation site, which is also consistent with our mutagenesis
studies.Various mechanisms of lentiviral Vif-mediated degrad-
ation of A3 proteins are slightly different
Slight differences in various mechanisms of lentiviral
Vif-mediated degradation of A3 proteins (Table 2) may
be attributed to different factors involved. First, the host
proteins involved in the degradation are different. Pri-
mate lentiviral Vifs require CBF-β as a regulator of the
folding of Vif to neutralize the A3 proteins, but non-
primate lentiviral Vifs, including those of FIV, BIV and
MVV, do not require CBF-β to neutralize the A3 pro-
teins. All lentiviral Vifs recruit Cul5 except for BIV Vif,
which was found here to recruit Cul2. Second, the
mechanisms of interaction between the Vif protein and
Cul protein are different. Primate lentiviral Vifs utilize a
highly conserved HCCH zinc-binding motif to bind with
Cul5. By contrast, BIV Vif may utilize the CCHC do-
main to bind with Cul2, while FIV and MVV may use a
novel method for recruiting Cul5.
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Overall, this study supplements our knowledge of the
mechanism of degradation of host antiviral proteins
induced by BIV Vif and MVV Vif. Our work described
the interaction between BIV Vif and btCul2 through a
previously unreported zinc binding loop [C-x1-C-x1-
H-x19-C] which may provide a foundation for further
studies on similar protein-protein interactions. The
CBF-β-independent degradation pathway suggests that
the degradation of btA3Z2-Z3 by BIV Vif and that of
oaA3Z2-Z3 by MVV Vif may require factors different
from CBF-β. These viruses and their hosts have co-evolved
various mutually antagonistic proteins, which over the long
evolutionary process have facilitated viral entry into new
hosts. Thus, our work may shed light on the course of
disease in cows and sheep, as well as the potential for
cross-species transmission of BIV or MVV. Further
studies to identify these factors may provide new in-
sights into the molecular mechanism(s) of Vif-mediated
neutralization of host innate immune defenses.
Methods
Plasmid construction
The genes encoding btEloB, btEloC, btCBF-β, btCul2,
btCul5, oaEloB, oaEloC, oaCBF-β, oaCul2 and oaCul5
were obtained by RT-PCR. Bovine total RNA was extracted
from MDBK cells, and ovine total RNA was extracted from
MDOK cells using TRIzol (Invitrogen, Carlsbad, CA)
separately. The following primers were used to amplify
the genes by RT-PCR: btEloB, forward (5′-ATGGACG
TGTTCCT CATGATC-3′) and reverse (5′-TCACTGC
ACAGCCT GTTCGTTG-3′); btEloC, forward (5′-AT
GGATGGAGAAGAGAAAAC-3′) and reverse (5′-TTA
ACAATCTA GGAAGTTC-3′); btCBF-β, forward (5′-A
TGCCGCGCGTCGTGCCCGAC-3′) and reverse (5′-C
TAGGGTCTTGTTGTCTTCTT-3′); btCul2, forward




loB, forward (5′-ATGGACG TGTTCCTCATGAT-3′) and
reverse (5′-TCACTGCACAGCCTGTTCGT-3′); oaEloC,
forward (5′-ATGGATGGAGAAGAGAAAAC-3′) and re-
verse (5′-TTAACA ATCTAGGAAGTTTG-3′); oaCBF-β,
forward (5′-ATGCCGCGCGTCGTGCCC GAC-3′) andTable 2 Comparison of various mechanisms of lentiviral Vif-m
Lentivirus E3 complex Method of binding with EloC
HIV Y BC box (SLQ)
SIV Y BC box (SLQ)
FIV Y BC box (TLQ)
BIV Y BC box (SLQ)
MVV Y BC box (SLQ)reverse (5′-CTAGGGTCTTGTTGTCTTCTT-3′); oaCul2,
forward (5′-ACACTAAACTTGCACAATGTCTTT-3′) and
reverse (5′-TCAGGCGACGTAG CTGTACTCATCT-3′);
and oaCul5, forward (5′-ATGGCGACGTCTAA TCTG
TT-3′) and reverse (5′-TTACGCCATATATATGAAA
G-3′). The amplified genes were inserted into the inter-
mediate pGEM-T-easy vector (Promega, Madison, WI)
to generate bt- and oaEB-T-easy, bt- and oaEC-T-easy,
bt- and oaCBF-β-T-easy, bt- and oa Cul2-T-easy and bt-
and oaCul5-T-easy.
The btA3Z2-Z3 and oaA3Z2-Z3 eukaryotic expression
plasmids were derived from BtA3Z2-Z3 and OaA3Z2-Z3
expression constructs described previously [37], and PC-
hVHL-HA was provided by Xiao-Fang Yu (Johns Hopkins
University, Baltimore, MD). The lentiviral Vifs chosen for
codon optimization (Sangon Biotech, Shanghai, China)
matched BIVBIM127 (gb M32690) and MVV Icelandic strain
1514 (gb M60610). The VR-btELoB-cmyc, btCul2-cmyc
and btCul5-cmyc plasmids were obtained by PCR amp-
lification from the btELoB-T-easy, bt-Cul2-T-easy and
btCul5-T-easy plasmids separately and subcloned into
the VR1012 vector for eukaryotic expression with a
cmyc tag added at the C-terminus. The VR-btELoC-
HA plasmid was obtained by PCR amplification from
btELoC-T-easy and subcloned into the VR1012 vector
for eukaryotic expression with a HA tag added at the
C-terminus. The VR-btCBF-β-flag plasmid was obtained
by PCR amplification from btCBF-β-T-easy and subcloned
into the VR1012 vector for eukaryotic expression with a
Flag tag added at the C-terminus. The VR-oaELoB-cmyc,
oaCul2-cmyc and oaCul5-cmyc plasmids were obtained
by PCR amplification from the oaELoB-T-easy, oaCul2-T-
easy and oaCul5-T-easy plasmids separately and subcloned
into the VR1012 vector for eukaryotic expression with a
cmyc tag added at the C-terminus. The VR-oaELoC-HA
plasmid was obtained by PCR amplification from oaELoC-
T-easy and subcloned into the VR1012 vector for
eukaryotic expression with a HA tag added at the C-
terminus. The VR-oaCBF-β-flag plasmid was obtained
by PCR amplification from oaCBF-β-T-easy and subcloned
into the VR1012 vector for eukaryotic expression with a
Flag tag added at the C-terminus.
VR-BIV Vif-cmyc is a eukaryotic plasmid expressing
the codon-optimized BIVBIM127 (gb M32690) Vif. It was
generated by adding a cmyc tag to the C-terminus of theediated degradation of A3 proteins
Cul2/Cul5 Method of binding with Cul CBF-β involved
Cul5 zinc finger Y
Cul5 zinc finger Y
Cul5 unknown N
Cul2 zinc binding loop N
Cul5 unknown N
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the VR1012 vector at the BamHI and NotI restriction
sites. VR-BIV Vif -HA was derived from VR-BIV Vif-cmyc
with primers that added an HA tag in frame at its C-
terminus. VR-btCul2-HA, and VR-btCul5-HA were simi-
larly obtained from corresponding cmyc-tagged plasmids
(VR-btCul2-cmyc and VR-btCul5-cmyc, respectively).
Via site-directed mutagenesis, VR-BIV Vif SLQ-AAA-
cmyc, VR-BIV Vif H102L-cmyc, VR-BIV Vif C111S-cmyc,
VR-BIV Vif C113S-cmyc, VR-BIV Vif H115L-cmyc, VR-
BIV Vif C134S-cmyc, VR-BIV Vif H149L-cmyc and VR-
BIV Vif C111S/ C113S-cmyc were derived from VR-BIV
Vif-cmyc. Meanwhile, VR-BIV Vif C111S/C113S-HA was
derived from VR-BIV Vif-HA. The btCul2, btCul5 and
btEloC mutants were engineered based on the correspond-
ing plasmids (VR-btCul2-cmyc, VR-btCul5-cmyc and
VR-btEloC-HA, respectively). These mutant constructs
were made using the QuickChange mutagenesis system
(Stratagene, La Jolla, CA) and confirmed by sequencing.
VR-MVV Vif-cmyc is a eukaryotic plasmid expressing
the codon-optimized MVV Icelandic strain 1514 vif. It
was generated by adding a cmyc tag to the C-terminus of
the codon-optimized MVV vif gene and then subcloned
into the VR1012 vector at the SalI and NotI restriction
sites.
VR-MVV Vif SLQ-AAA-cmyc was derived from VR-
MVV Vif-cmyc via site-directed mutagenesis, and the
oaCul2, oaCul5 and oaEloC mutants were engineered
based on the corresponding plasmids (VR-oaCul2-cmyc,
VR-oaCul5-cmyc and VR-oaEloC-HA, respectively). VR1012
clone using the QuickChange mutagenesis system and
confirmed by sequencing.
The expression vectors VR-HIV Vif-cmyc, PC-hA3G–
HA, VR-hEC-HA, VR- hCBF-β-Flag and the infectious
molecular clone pNL4-3ΔVif were described previously
[12,16,51]. The expression vectors VR-hCul5-cmyc, VR-
hCul5 ΔNedd8-cmyc and VR-hCul1K720R-cmyc were
derived from VR-hCul5-HA, VR-hCul5 ΔNedd8-HA and
VR-hCul1K720R-HA, respectively, as described previ-
ously [43,52].
Cells and transfections
HEK293T (CRL-11268) cells, MDBK (CCL-22) cells
and MDOK (CRL-1633) cells were purchased from
the American Type Culture Collection (ATCC, Manassas,
VA). MAGI-CCR5 cells (catalog number 3522) were
obtained from the NIH AIDS Research and Reference
Reagent Program (NIH-ARRRP). HEK293T and MAGI-
CCR5 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) at 37°C with 5% CO2. MDBK cells were cul-
tured in DMEM supplemented with 10% horse serum at
37°C with 5% CO2. MDOK cells were cultured in Mini-
mum Essential Medium (MEM) supplemented with 10%FBS at 37°C with 5% CO2. Transfections of 293 T cells
were performed using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions.Antibodies
The following antibodies were used in the present study:
anti-HA mouse monoclonal antibody (mAb; Covance,
Emeryville, CA), anti-cmyc mouse mAb (Millipore, Billerica,
MA), anti-Flag mouse mAb (Sigma, St. Louis, MO), anti-
tubulin mouse mAb (Covance), anti-Cul2 rabbit polyclonal
antibody (pAb; Santa Cruz Biotechnology, Santa Cruz,
CA), anti-Cul5 rabbit pAb (Santa Cruz Biotechnology),
anti-CBF-β mouse mAb (Santa Cruz Biotechnology), anti-
EloB rabbit pAb (Santa Cruz Biotechnology) and anti-
EloC mouse mAb (Santa Cruz Biotechnology).Western blotting
Cells were collected 48 h post-transfection and lysed
with sodium dodecyl sulfate (SDS) sample buffer. The
samples were boiled for 20 min and separated by SDS-
polyacrylamide gel electrophoresis (PAGE) and then trans-
ferred onto nitrocellulose membranes (Whatman, Kent,
UK). After blocking in 5% nonfat milk, the membranes
were probed with various primary antibodies against
proteins of interest. Secondary antibodies were alkaline
phosphatase-conjugated anti-rabbit, anti-mouse IgG (Jackson
Immunoresearch, West Grove, PA). Immunoreactions were
detected with 5-bromo-4-chloro-3-indolylphosphate (BCIP)
and nitro blue tetrazolium chloride (NBT) solutions.MG132 inhibition assay
To determine if the degradation of btA3Z2-Z3 by BIV
Vif or that of oaA3Z2-Z3 by MVV Vif is proteasome-
dependent, 293 T cells were treated with the proteasome
inhibitor MG132 (Sigma–Aldrich) at 10 μM and DMSO
as negative control at 36 h after transfection with indi-
cated plasmids. At 48 h after transfection, 293 T cells
were harvested and analyzed by Western blotting.TPEN inhibition assay
To explore if Zn is significant for the degradation of
A3Z2-Z3 induced by Vif, 293 T cells were treated with
TPEN at 3.5 μM and DMSO as negative control at 36 h
after transfection with indicated plasmids. At 48 h after
transfection, 293 T cells were harvested and analyzed by
Western blotting.CHX-treated A3Z2-Z3 stability assay
At 36 h after transfection with indicated plasmids, 293 T
cells were treated with CHX (Sigma–Aldrich) at the final
concentration of 100 μg/ml for 0, 6, 12, 24 h and then
harvested and analyzed by Western blotting.
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At 48 h after transfection with indicated plasmids, 293 T
cells were obtained and dissociated in lysis buffer (50 mM
Tris, pH 7.5, with 150 mM NaCl, 1% Triton X-100 and
complete protease inhibitor cocktail tablets) at 4°C for 1 h,
followed by centrifugation at 10,000 × g for 10 min at 4°C
to pellet the cell debris. The pre-cleared supernatants were
collected and then mix with anti-HA Ab-conjugated
agarose beads (Roche, Mannheim, Germany), followed
by incubation at 4°C for 3 h. Alternatively, the pre-cleared
supernatants were collected and incubated with mouse
anti-cmyc (Millipore) for 1 h and then mix with Protein
G-agarose (Roche), followed by incubation at 4°C for 3 h.
The beads were washed three times with wash buffer
(20 mM Tris, pH 7.5, with 100 mM NaCl, 0.1 mM EDTA
and 0.05% Tween 20), and the pellet was resuspended in
30 μl glycine HCl (pH 2.0) elution buffer. The eluted
materials were subsequently analyzed by Western blotting.
Viral infectivity assay
Viral infection was determined by a multinuclear activation
of a galactosidase indicator (MAGI) assay as described pre-
viously [12]. Briefly, MAGI-CCR-5 cells were seeded in 24-
well plates 1 day before infection. The MAGI-CCR-5 cells
were infected at 20–30% confluency. Virus input was nor-
malized by the level of p24. Equal p24 units of virus
samples were mixed with 20 μg/ml DEAE-dextran and
incubated with MAGI-CCR5 cells for 2 h. The initial
infection period was terminated by addition of fresh
DMEM. After incubation for 48 h at 37°C in a 5% CO2
incubator, supernatants were removed, and the cells were
fixed with 500 μl of fixing solution (1% formaldehyde and
0.2% glutaraldehyde in PBS) for 5 min and stained with 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal).
As β-galactosidase activity is under the control of the
HIV-1 long terminal repeat (LTR) promoter in this system,
positive blue dots representing β-galactosidase activity
were counted to determine viral infectivity.
Sequence analysis and modeling
The homology model of BIV Vif was built by Discovery
Studio 2.1 software package using the crystal structure of
tatD DNase of E. Coli. (PDB ID: 1XWY) as the template.
Modeling was performed at the medium optimization
level with refined loop parameters, and no additional re-
straints were used. Ten models were built, and the model
with the best score was chosen.
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